Investors Buy High Volume of Takeda Pharmaceutical Put Options (TAK)

Takeda Pharmaceutical Co Ltd (NYSE:TAK) saw some unusual options trading activity on Thursday. Stock traders acquired 5,006 put options on the stock. This represents an increase of approximately 6,080% compared to the average daily volume of 81 put options.

Shares of TAK traded up $0.18 during trading hours on Friday, hitting $17.56. The company had a trading volume of 86,084 shares, compared to its average volume of 2,650,255. The firm has a market capitalization of $28.17 billion, a PE ratio of 16.42, a PEG ratio of 62.15 and a beta of 0.66. Takeda Pharmaceutical has a 12 month low of $15.50 and a 12 month high of $21.95. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.22 and a quick ratio of 2.81.

Several institutional investors and hedge funds have recently modified their holdings of the company. Shelton Capital Management bought a new position in Takeda Pharmaceutical during the first quarter worth about $46,000. Hudock Capital Group LLC purchased a new position in Takeda Pharmaceutical during the 1st quarter worth $26,000. Global Retirement Partners LLC boosted its holdings in Takeda Pharmaceutical by 63.3% during the 1st quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock worth $70,000 after acquiring an additional 1,326 shares during the last quarter. Assetmark Inc. purchased a new position in Takeda Pharmaceutical during the 1st quarter worth $28,000. Finally, Shine Investment Advisory Services Inc. purchased a new position in shares of Takeda Pharmaceutical in the 1st quarter worth about $28,000. 4.42% of the stock is currently owned by institutional investors.

Several research analysts have recently weighed in on TAK shares. Goldman Sachs Group reiterated a “buy” rating on shares of Takeda Pharmaceutical in a report on Tuesday, March 19th. Zacks Investment Research lowered shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, April 27th. Finally, ValuEngine lowered shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2019/05/17/investors-buy-high-volume-of-takeda-pharmaceutical-put-options-tak.html.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Story: Google Finance Portfolio Workaround

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.